Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality

Joshua R. Niska; Terence T. Sio; Thomas B. Daniels; Staci E. Beamer; Dawn E. Jaroszewski; Helen J. Ross; Harshita R. Paripati; Steven E. Schild

doi:10.21037/jtd.2018.04.169

Editorial

Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality

Joshua R. Niska, Terence T. Sio, Thomas B. Daniels, Staci E. Beamer, Dawn E. Jaroszewski, Helen J. Ross, Harshita R. Paripati, Steven E. Schild

Abstract

Stereotactic body radiotherapy (SBRT) is increasingly used to treat stage I non-small cell lung cancer (NSCLC). In 2004, less than 0.5% of these cases were managed with SBRT. By 2011, SBRT accounted for 8.7% of cases (1).

Editorial

Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality

Abstract

Article Options

Download Citation

Share